Basic safety and also immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two products: a couple of open up, non-randomised cycle 1/2 studies via Russia.
https://www.selleckchem.com/products/sacituzumab-govitecan.html